An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling.
Overview
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 16000 Praha 6, Czech Republic
- WEHI, 1G Royal Parade, Parkville, Victoria 3052, Australia
- Department of Medical Biology, Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Parkville, Victoria, 3010, Australia
- Department of Genetics and Microbiology, Faculty of Science, Charles University, 12840 Prague 2, Czech Republic
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
- Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Abstract
Insulin and insulin-like growth factors (IGF-1 and IGF-2) regulate metabolism, growth, and development via related receptors. In contexts such as brain function or fetal development, coordinated signaling by all three hormones is essential. We report the engineering of [GluB10, D-HisB24, GlyB31, TyrB32]-insulin (1Ins), an analog with high affinity for IR-A, IR-B, and especially IGF-1R. 1Ins binds IGF-1R ~1000-fold more strongly than native insulin, approaching IGF-1 levels. Cryo–electron microscopy structures reveal how minimal substitutions in 1Ins enable effective binding to both IR-A and IGF-1R. In neuronal cells, 1Ins robustly activates both IR and IGF-1R pathways, promotes survival, and exceeds native ligands in neuroprotective assays. In vivo, 1Ins regulates glucose effectively in mice and rats. Phosphoproteomic profiling confirms dual pathway activation and identifies targets specific to 1Ins. These findings demonstrate that rational design of dual-receptor agonists can yield potent, versatile ligands with therapeutic promise in metabolic control, neuroprotection, and regeneration.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- ebi.ac.uk/
emdb/ , at EMBL-EBI; found in “Data, code, and materials availability:”emd-49260 - ebi.ac.uk/
emdb/ , at EMBL-EBI; found in “Data, code, and materials availability:”emd-49261 - rcsb.org/
structure/ , at PDB; found in “Data, code, and materials availability:”9ncn - rcsb.org/
structure/ , at PDB; found in “Data, code, and materials availability:”9nco
Data, code, and materials availability
All data and code needed to evaluate and reproduce the results in the paper are present in the paper and/
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 14 authors, 11 MeSH terms, 4 funders, 109 references.
Cite
This paper
Selicharová, I., Kirk, N. S., Kertisová, A., Lubos, M., Mitrová, K., Ticháčková, T., Žáková, L., Chrudinová, M., Březinová, J., Harant, K., Voldřich, J., Hájek, M., Huffman, D. M., & Jiráček, J. (2026). An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling. Science advances, 12(20), eaeb7558. https://
BibTeX
@article{selicharova2026
author = {Selicharová, Irena and Kirk, Nicholas S and Kertisová, Anna and Lubos, Marta and Mitrová, Katarína and Ticháčková, Terezie and Žáková, Lenka and Chrudinová, Martina and Březinová, Jana and Harant, Karel and Voldřich, Jan and Hájek, Miroslav and Huffman, Derek M and Jiráček, Jiří},
title = {{An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling}},
journal = {Science advances},
year = {2026},
month = may,
volume = {12},
number = {20},
pages = {eaeb7558},
publisher = {American Association for the Advancement of Science},
issn = {2375-2548},
doi = {10.1126/
url = {https://
pmid = {42139356},
pmcid = {PMC13178572}
}
RIS
TY - JOUR
AU - Selicharová, Irena
AU - Kirk, Nicholas S
AU - Kertisová, Anna
AU - Lubos, Marta
AU - Mitrová, Katarína
AU - Ticháčková, Terezie
AU - Žáková, Lenka
AU - Chrudinová, Martina
AU - Březinová, Jana
AU - Harant, Karel
AU - Voldřich, Jan
AU - Hájek, Miroslav
AU - Huffman, Derek M
AU - Jiráček, Jiří
TI - An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling
T2 - Science advances
J2 - Sci Adv
PY - 2026
DA - 2026/
VL - 12
IS - 20
SP - eaeb7558
SN - 2375-2548
PB - American Association for the Advancement of Science
DO - 10.1126/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1126/
"type": "article-journal",
"title": "An engineered insulin analog with dual insulin and IGF-1 receptor agonism and distinct signaling",
"container-title": "Science advances",
"author": [
{
"family": "Selicharová",
"given": "Irena"
},
{
"family": "Kirk",
"given": "Nicholas S"
},
{
"family": "Kertisová",
"given": "Anna"
},
{
"family": "Lubos",
"given": "Marta"
},
{
"family": "Mitrová",
"given": "Katarína"
},
{
"family": "Ticháčková",
"given": "Terezie"
},
{
"family": "Žáková",
"given": "Lenka"
},
{
"family": "Chrudinová",
"given": "Martina"
},
{
"family": "Březinová",
"given": "Jana"
},
{
"family": "Harant",
"given": "Karel"
},
{
"family": "Voldřich",
"given": "Jan"
},
{
"family": "Hájek",
"given": "Miroslav"
},
{
"family": "Huffman",
"given": "Derek M"
},
{
"family": "Jiráček",
"given": "Jiří"
}
],
"container-title-short":
"volume": "12",
"issue": "20",
"page": "eaeb7558",
"DOI": "10.1126/
"PMID": "42139356",
"PMCID": "PMC13178572",
"ISSN": "2375-2548",
"publisher": "American Association for the Advancement of Science",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
15
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1093/brain/awac309
- Cerebrovascular insulin receptors are defective in Alzheimer's disease.Journal: Brain : a journal of neurologyIn common: mouse, cellular / molecular, 4 references
- [2] doi:10.1038/s41598-025-31601-1
- Reduced IGF-1 signaling fails to limit Alzheimer's disease progression in a novel rat model of IGF-1R haploinsufficiency.Journal: Scientific reportsIn common: rat, mouse, cellular / molecular, 3 references
- [3] doi:10.1038/s44320-024-00050-9 [code]
- µPhos: a scalable and sensitive platform for high-dimensional phosphoproteomics.Journal: Molecular systems biologyIn common: mouse, cellular / molecular, 4 references
- [4] doi:10.1038/s44318-025-00400-9
- PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division.Journal: The EMBO journalIn common: cellular / molecular, 4 references
- [5] doi:10.1016/j.omtm.2023.101149
- Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II.Journal: Molecular therapy. Methods & clinical developmentIn common: 3 references
- [6] doi:10.3389/fphys.2021.825816
- Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives.Journal: Frontiers in physiologyIn common: cellular / molecular, 3 references
- [7] doi:10.1038/s41467-025-66356-w [code]
- Bipolar and schizophrenia risk gene AKAP11 encodes an autophagy receptor coupling the regulation of PKA kinase network homeostasis to synaptic transmission.Journal: Nature communicationsIn common: mouse, cellular / molecular, 3 references
- [8] doi:10.1007/s00702-025-02952-w
- Species-specific sensitivity to intracerebroventricular streptozotocin in rats and mice highlights pathways and proteins relevant to Alzheimer's disease.Journal: Journal of neural transmission (Vienna, Austria : 1996)In common: rat, mouse, cellular / molecular, 2 references
- [9] doi:10.1016/j.celrep.2022.111698
- Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis.Journal: Cell reportsIn common: cellular / molecular, 2 references
- [10] doi:10.1016/j.ebiom.2025.105791
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.Journal: EBioMedicineIn common: mouse, cellular / molecular, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
